Owing to the different hypersensitivity conditions and their manifestations in paediatric ALL patients, guidelines have been proposed by clinical physicians and researchers when switching between distinct L-asparaginase formulations, in search of a better L-asparaginase treatment outcome for the patients. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.